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Salvage use of allogeneic hematopoietic stem cell
transplantation after reduced intensity conditioning
from unrelated donors in multiple myeloma. A study
by the Plasma Cell Disorders subcommittee of the
European Group for Blood and Marrow Transplant
Chronic Malignancies Working Party
Despite major improvements in the treatment of mul-
tiple myeloma (MM), the majority of patients will even-
tually relapse.1 Those patients may benefit most from the
potentially curative effect of graft versus myeloma effect
of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) and its combination with potent anti-myelo-
ma agents, especially if high-risk features are present at
diagnosis.2 Of late, different studies have evaluated the
use of novel drugs including panobinostat, carfilzomib,
daratumumab, elotuzumab and ixazomib in the context
of relapse with very promising results.3-8 We recently
showed that the number of patients who received an
allo-HSCT for MM in Europe is steadily increasing, and
about 70% of cases are performed at a later stage of the
disease, mainly following failure after one or two autolo-
gous HSCTs (auto-HSCT).9 Herein, we aim to present a
refined analysis considering the current most common
indication for allogeneic HSCT in MM, namely  salvage
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Table 1. Patient and transplantation characteristics. 
10/10 HLA MUD 9/10 HLA MMUD Cord Blood
N=419 N=93 N=58
Median age at Allo-HSCT (range) 55 (30-74) 55 (19 - 69) 57 (24-69)
Sex (M/F) 260 (62%) / 159 (38%) 58 (62%) / 35 (38%) 28 (48%) / 30 (52%)
Previous number of Auto-HSCTs
1 Auto-HSCT 257 (61%) 52 (56%) 27 (47%)
2 Auto-HSCTs 162 (39%) 41 (44%) 31 (53%)
Median time Auto-Allo HSCT (Months) 13 22 27
International Staging System (ISS) 
I 34 (11%) 6 (8%) 3 (8%)
II 60 (16%) 13 (18%) 6 (16%)
III 268 (73%) 53 (74%) 28 (76%)
Missing N=57 N=21 N=21
Myeloma subtype
IgG 299 (72%) 63 (69%) 43 (75%)
IgA 108 (26%) 25 (27%) 14 (25%)
Light chain 10 (2%) 4 (4%) -
Missing N=2 N=1 N=1
Cytogenetic abnormalities
High-risk [t(4;14), del17p] 12 2 2
Other abnormalities (del13q, others) 94 3 6
Not reported in the registry 313 88 50
Disease status at Allo-HSCT 
>PR 155 (38%) 20 (22%) 15 (26%)
PR 145 (36%) 41 (45%) 23 (40%)
<PR 109 (26%) 30 (33%) 20 (34%)
Missing N=10 N=2 -
T-cell depletion
Yes/No 284 (68%) / 135 (32%) 72 (77%) / 21 (23%) 10 (17%) / 48 (83%)
Reduced-Intensity Conditioning
BU-based 129 (31%) 27 (29%) 4 (7%)
TBI-based 125 (30%) 26 (28%) 48 (83%)
Others 165 (39%) 40 (43%) 6 (10%)
HLA matching 
MM on A locus − 19 (20%) −
MM on B locus − 10 (11%) −
MM on C locus − 35 (38%) −
MM on DQ locus − 20 (22%) −
MM on DR locus − 9 (9%) −
6/6 CB − − 2 (3%)
5/6 CB − − 14 (24%)
4/6 CB − − 42 (73%)
Year of Allo-HSCT
2001-2007 54 (13%) 17 (18%) 13 (22%)
2008-2013 365 (87%) 76 (82%) 45 (78%) 
HLA: human leukocyte antigen; MUD: matched unrelated donors; MMUD: mismatched unrelated donors; HSCT: hematopoietic stem cell transplantation; CB: cord blood;
Auto: autologous; Allo: allogeneic; PR: partial response; BU: busulfan; TBI: total body irradiation; IgG: immunoglobulin G; IgA: immunoglobulin A.
allo-HSCT after one or two auto-HSCTs using reduced-
intensity conditioning (RIC) and an alternative donor.
Therefore,  we contrasted the outcomes of patients
receiving cord blood (CB) allo-HSCT with those of com-
parable patients receiving peripheral blood stem cells
(PBSCs) during the same period of time from either 10/10
human leukocyte antigen (HLA)-matched unrelated
donors (MUD) or 9/10 HLA-mismatched unrelated
donors (MMUD). 
We included MM patients who received RIC allo-
HSCT from unrelated donors after one or two auto-
HSCTs between January 2001 and December 2013, as
reported in the European Group for Blood and Marrow
Transplant (EBMT) registry. Only patients with complete
data on HLA typing were included. HLA results were
reviewed and classified by an independent HLA expert
on HLA A,B,C,DR,DQ for patients receiving allo-HSCT
from PBSCs and on HLA A,B (generic level) DR (allelic
level) for those receiving allo-HSCT from CB. There were
570 patients in total; 346 (61%) were males, median age
at allo-HSCT was 55 years (range: 19-74), the
immunoglobulin subtype was immunoglobulin G (IgG) in
48% of patients, light chain in 26% and immunoglobulin
A (IgA) in 20%. Overall, 62% were in stage III according
to the International Staging System (ISS) classification.
Cytogenetic data was absent in 451 (79%) patients; this
could be due to the fact that in most cases cytogenetic
testing was not done, was done but not reported in the
registry, or, the least likely scenario, was done and found
to be normal. For the remaining 119 (21%) patients, kary-
otype abnormalities were reported, with the majority
affecting del(13q), and there were 12 high-risk patients
with t(4;14) and/or del (17p). Allo-HSCT was performed
after a median time of 15 months (range: 3-46) following
one (n=336, 59%) or two (n=234, 41%) auto-HSCTs.
Unrelated donors were 10/10 HLA-MUD for 419 (74%)
patients, 9/10 HLA-MMUD for 93 (16%) patients and at
least 4/6 HLA-matched CB in 58 (10%) patients (19 sin-
gle, 39 double). In the 9/10 MMUD group, the mismatch
concerned the A locus in 19 (20%) patients, the B locus
in 10 (11%), the C locus in 35 (38%), the DQ locus in 20
(22%) and the DR locus in 9 (9%) patients. In the CB
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Figure 1. Transplantation outcomes according to the different hematopoietic stem cells sources. (A) Overall survival, (B) Progression-Free Survival, (C) Relapse
incidence and (D) Non-Relapse Mortality. MUD: matched unrelated donors; MMUD: mismatched unrelated donors; CB: cord blood; Allo-HSCT: allogeneic
hematopoietic stem cell transplantation; CI: confidence interval. 
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group, the degree of HLA matching was as follows: 6/6
HLA-matched in 2 (3%) patients, 5/6 HLA-mismatched
in 14 (24%) patients, and 4/6 HLA-mismatched in 42
(73%) of patients. At transplantation, at least 399 (70%)
of patients were in partial response (PR), among them,
122 (21%) reached complete remission (CR). In the MUD
and MMUD groups, RIC included fludarabine, busulfan
and anti-thymocyte globulin (ATG) in 45% of patients,
fludarabine and low-dose total body irradiation (TBI) in
30% of patients, and fludarabine and melphalan in addi-
tion to either ATG, campath or bortezomib in 26% of
patients. In the CB group, RIC mainly included
cyclophosphamide, fludarabine and low-dose TBI (83%
of patients). There were no significant differences
between the three groups according to the different dis-
eases and patients' characteristics as cited above. Disease
and transplantation characteristics according to the dif-
ferent donor groups are described in Table 1.
The engraftment rate was 94%, 96% and 89% in the
MUD, MMUD and CB groups, respectively. Acute 
graft-versus-host disease (GvHD) grade II-IV occurred in
33%, 41% and 42% of patients in the three groups,
respectively, while chronic GvHD was present in
152/373 (41%) patients (56 limited, 96 extensive), 39/83
(47%) (15 limited, 24 extensive) and 15/49 (31%) (11 lim-
ited, 4 extensive), respectively.  After a median follow-up
of 26 months, the probability of overall survival (OS) for
patients at three years was 47% (95% confidence interval
(CI): 41-52), 45% (95% CI: 34-56) and 38% (95% CI: 25-
51) in the MUD, MMUD and CB groups, respectively. At
five years the probability of OS was 33% (95% CI: 26-
40), 39% (95% CI: 28-51) and 25% (95% CI: 12-39),
respectively, with a median OS of 32 months, 31 months
and 20 months, respectively (P=0.35) (Figure 1A). At
three years the probability of progression-free survival
(PFS) for the MUD, MMUD and CB groups was 25%
(95% CI: 21-30), 31% (95% CI: 22-42) and 19% (95%
CI: 9-30), respectively, P=0.10. At five years the probabil-
ity of PFS was 14% (95% CI: 9-19), 27% (95% CI: 18-38)
and 4% (95% CI: 1-16), respectively, with a median PFS
of 12.7 months, 12 months and 9.2 months, respectively
(Figure 1B). The cumulative incidence of relapse for the
MUD, MMUD and CB groups at three years was 50%
(95% CI: 44-55), 35% (95% CI: 25-46) and 54% (95%
CI: 40-67), and at five years it reached 58% (95% CI: 52-
65), 37% (95% CI: 27-48) and 69% (95% CI: 52-81),
respectively (P=0.013 for MMUD versus all others) (Figure
1C). The non-relapse mortality (NRM) rate at two years
was 22% (95% CI: 18-26), 33% (95% CI: 23-43) and
27% (95% CI: 16-39) in the MUD, MMUD and CB
groups, respectively, P=0.23, at five years the rate was
28% (95% CI: 23-33), 35% (95% CI: 25-46) and 27%
(95% CI: 16-39), respectively. Among those patients con-
sidered high-risk according to cytogenetics, no significant
difference was observed in terms of OS and PFS between
the three groups.
The principal finding of our study is the similar out-
come of HLA 9/10 mismatched unrelated donors and
HLA 10/10 matched unrelated donors. Notably, even if
not significant, the Kaplan-Meier curves of PFS and OS in
the HLA 9/10 MMUD group suggest a trend for a better
outcome in the long-term. This may be caused by a
stronger graft versus myeloma effect after HLA 9/10
MMUD as supported by a significantly lower incidence
of relapse. Despite its low number, the CB group shows
the feasibility of this kind of cell source, as published
studies on this topic are very limited; apart from a recent
study by the EBMT reporting results of 95 CB allo-HSCT
in MM,10 there is one additional study which was per-
formed using data from the Japanese registry,11 reporting
on a total of 86 patients between 2001 and 2011. In both
of these aforementioned studies, myeloablative
chemotherapy and RIC were included, along with
patients with different allo-HSCT indications (first-line,
tandem auto-allo HSCT and further treatments). In our
study, we considered the current most used indication for
allogeneic HSCT in MM, which is the salvage allo-HSCT
after one or two auto-HSCTs using RIC. Even if not sig-
nificant, the outcome following CB transplantation
seems to be worse in comparison to HLA 10/10 MUD or
9/10 MMUD. The main concern for all alternative donor
options is the high risk of relapse. In the manner of autol-
ogous transplantation, maintenance strategies with novel
agents alone or in combination with donor lymphocyte
infusions should be investigated following salvage allo-
geneic transplantation in order to reduce the risk of
relapse. Similar to other registry studies, the main weak-
ness of our study is the unknown patient selection.
However, the short median interval of only 15 months
between the last autograft and allogeneic stem cell trans-
plantation suggests a selection of high-risk patients in the
presented registry study. Finally, it might not be feasible
to perform the necessary clinical trials to compare differ-
ent regimens or drug association to allogeneic transplan-
tation, and determine which are most suitable for partic-
ular subgroups of relapsed/refractory MM patients, how-
ever, gaining cautious insights from subgroup analyses as
we present herein could help in guiding clinicians in their
daily practice. In conclusion, salvage RIC allo-HSCT from
alternative unrelated donors after a short remission dura-
tion of one or two auto-HSCTs is a feasible treatment
option which offers a degree of long-term survival. HLA
9/10 mismatched or HLA10/10 matched unrelated
donors are the preferential alternative donor sources.
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